Cargando…
甲氨蝶呤鞘内注射治疗脑膜癌病疗效和安全性的临床观察
BACKGROUND AND OBJECTIVE: Leptomeningeal carcinomatosis is a rare type of metastatic tumors of the central nervous system. In recent years, with the improvement of neoplasms therapies and longer survival of patients by better systemic control, incidence of leptomeningeal metastases has increased eve...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973059/ https://www.ncbi.nlm.nih.gov/pubmed/27215452 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.05.08 |
_version_ | 1783326542135296000 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Leptomeningeal carcinomatosis is a rare type of metastatic tumors of the central nervous system. In recent years, with the improvement of neoplasms therapies and longer survival of patients by better systemic control, incidence of leptomeningeal metastases has increased every year. However, there is still lack of effective therapies. The aim of this study is to investigate the efficacy, security and prognosis of intrathecal chemotherapy with methotrexate (MTX) in the treatment of neoplastic meningitis. METHODS: A total of 27 patients were enrolled. We investigated clinical features and cerebrospinal fluid (CSF) examination results retrospectively, and analyzed the adverse reactions as well as prognosis after intrathecal chemotherapy. RESULTS: All 27 patients were treated by intrathecal MTX, 70.4% had clinical remission, however, there was no significant difference in CSF pressure and CSF biochemical changes. We observed that 55.6% patients were all appropriate, 25.9% appeared lower limb numbness and mild pain, no serious irreversible adverse reactions occurred. Median overall survival was 4 months. CONCLUSION: We suggest that intrathecal administration of MTX is associated with improvement of symptoms of leptomeningeal metastasis patients and no severe adverse events observed. |
format | Online Article Text |
id | pubmed-5973059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59730592018-07-06 甲氨蝶呤鞘内注射治疗脑膜癌病疗效和安全性的临床观察 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Leptomeningeal carcinomatosis is a rare type of metastatic tumors of the central nervous system. In recent years, with the improvement of neoplasms therapies and longer survival of patients by better systemic control, incidence of leptomeningeal metastases has increased every year. However, there is still lack of effective therapies. The aim of this study is to investigate the efficacy, security and prognosis of intrathecal chemotherapy with methotrexate (MTX) in the treatment of neoplastic meningitis. METHODS: A total of 27 patients were enrolled. We investigated clinical features and cerebrospinal fluid (CSF) examination results retrospectively, and analyzed the adverse reactions as well as prognosis after intrathecal chemotherapy. RESULTS: All 27 patients were treated by intrathecal MTX, 70.4% had clinical remission, however, there was no significant difference in CSF pressure and CSF biochemical changes. We observed that 55.6% patients were all appropriate, 25.9% appeared lower limb numbness and mild pain, no serious irreversible adverse reactions occurred. Median overall survival was 4 months. CONCLUSION: We suggest that intrathecal administration of MTX is associated with improvement of symptoms of leptomeningeal metastasis patients and no severe adverse events observed. 中国肺癌杂志编辑部 2016-05-20 /pmc/articles/PMC5973059/ /pubmed/27215452 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.05.08 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 临床研究 甲氨蝶呤鞘内注射治疗脑膜癌病疗效和安全性的临床观察 |
title | 甲氨蝶呤鞘内注射治疗脑膜癌病疗效和安全性的临床观察 |
title_full | 甲氨蝶呤鞘内注射治疗脑膜癌病疗效和安全性的临床观察 |
title_fullStr | 甲氨蝶呤鞘内注射治疗脑膜癌病疗效和安全性的临床观察 |
title_full_unstemmed | 甲氨蝶呤鞘内注射治疗脑膜癌病疗效和安全性的临床观察 |
title_short | 甲氨蝶呤鞘内注射治疗脑膜癌病疗效和安全性的临床观察 |
title_sort | 甲氨蝶呤鞘内注射治疗脑膜癌病疗效和安全性的临床观察 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973059/ https://www.ncbi.nlm.nih.gov/pubmed/27215452 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.05.08 |
work_keys_str_mv | AT jiǎāndiélìngqiàonèizhùshèzhìliáonǎomóáibìngliáoxiàohéānquánxìngdelínchuángguānchá AT jiǎāndiélìngqiàonèizhùshèzhìliáonǎomóáibìngliáoxiàohéānquánxìngdelínchuángguānchá AT jiǎāndiélìngqiàonèizhùshèzhìliáonǎomóáibìngliáoxiàohéānquánxìngdelínchuángguānchá AT jiǎāndiélìngqiàonèizhùshèzhìliáonǎomóáibìngliáoxiàohéānquánxìngdelínchuángguānchá AT jiǎāndiélìngqiàonèizhùshèzhìliáonǎomóáibìngliáoxiàohéānquánxìngdelínchuángguānchá AT jiǎāndiélìngqiàonèizhùshèzhìliáonǎomóáibìngliáoxiàohéānquánxìngdelínchuángguānchá AT jiǎāndiélìngqiàonèizhùshèzhìliáonǎomóáibìngliáoxiàohéānquánxìngdelínchuángguānchá AT jiǎāndiélìngqiàonèizhùshèzhìliáonǎomóáibìngliáoxiàohéānquánxìngdelínchuángguānchá AT jiǎāndiélìngqiàonèizhùshèzhìliáonǎomóáibìngliáoxiàohéānquánxìngdelínchuángguānchá |